The apparent non-essentiality of KAT2B and NELF for normal development, together with their acquired dependency in aggressive breast cancer, highlight the exciting prospect of developing therapeutic candidates to target NELF-E-KAT2B in cancer. This evidence concerns the gene KAT2B and breast carcinoma.